Ed Feener
Oprichter bij KALVISTA PHARMACEUTICALS, INC.
Vermogen: 764 280 $ op 30-04-2024
Actieve functies van Ed Feener
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-11-2016 | - |
| Oprichter | 26-03-2004 | - | |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Oprichter | 01-01-2011 | - |
| Corporate Officer/Principal | 01-01-2011 | - |
Loopbaan van Ed Feener
Eerdere bekende functies van Ed Feener
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Harvard Medical School | Corporate Officer/Principal | 01-07-1989 | 01-10-2016 |
Opleiding van Ed Feener
| Boston University | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 4 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Founder | 2 |
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
